Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ElixSure

This article was originally published in The Tan Sheet

Executive Summary

Alterna extends its children's ElixSure line with spill-resistant formulations of ElixSure Liquid Allergy (diphenhydramine 12.5 mg) in bubble gum flavor and ElixSure EX Liquid Expectorant (guaifenesin 50 mg) in strawberry. The products come in 4 oz. bottles for $5.99 each, and will be available in early fall. The extensions add to the line's current formulations, which include Congestion (pseudoephedrine HCl), Cough (dextromethorphan HBr) and Fever/Pain. Alterna announced its acquisition of the ElixSure line from Taro Consumer in March (1"The Tan Sheet," March 7, 2005, p. 11)...

You may also be interested in...



Taro Readies Branded OTC Exodus With ElixSure, Kerasal Divestiture

Taro's divestiture of its ElixSure cough/cold medicine and Kerasal moisturizer brands in North America to Alterna signals the firm's exit from the branded OTC drug market

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel